SAN DIEGO, CA--(MARKET WIRE)--Jul 16, 2007 -- Protein Polymer Technologies, Inc. (OTC BB:PPTI.OB - News), a biotechnology device company that is a pioneer in protein design and synthesis, announced today that they have entered into an agreement with a multinational biotechnology device company. According to the agreement, PPTI will provide genetically engineered protein polymer biomaterials for use in the prevention of post-surgical adhesions. “This agreement further demonstrates our core competency; developing novel protein polymer biomaterials for challenging medical applications such as the prevention of surgical adhesions,” said William N. Plamondon, Chief Executive Officer of PPTI. “Additionally, it furthers the progression of our plan to establish relationships with partners that will ultimately market the products. This relationship adds to the six others we have in product development which includes our license agreements with Spine Wave, Inc. and Genencor International, Inc.”
